KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Operations: 2010-2024

Historic Cash from Operations for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $172.0 million.

  • Supernus Pharmaceuticals' Cash from Operations fell 215.22% to -$61.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year decrease of 58.33%. This contributed to the annual value of $172.0 million for FY2024, which is 54.79% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Cash from Operations of $172.0 million as of FY2024, which was up 54.79% from $111.1 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Cash from Operations ranged from a high of $172.0 million in FY2024 and a low of $111.1 million during FY2023.
  • For the 3-year period, Supernus Pharmaceuticals' Cash from Operations averaged around $133.3 million, with its median value being $116.8 million (2022).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Cash from Operations declined by 8.14% in 2021, and later spiked by 54.79% in 2024.
  • Supernus Pharmaceuticals' Cash from Operations (Yearly) stood at $138.4 million in 2020, then decreased by 8.14% to $127.1 million in 2021, then dropped by 8.10% to $116.8 million in 2022, then dropped by 4.91% to $111.1 million in 2023, then soared by 54.79% to $172.0 million in 2024.